SOPHiA so good with $30m raise by genetics ace
SOPHiA GENETICS, part of Mike Lynch’s Invoke Capital investment portfolio in Cambridge, has raised $30 million in Series D funding to accelerate global rollout of its data driven medicine technology.
The Series D round was led by Balderton Capital with new investor 360° Capital Partners, and existing investors Invoke Capital and Alychlo participating. The haul takes the total raised by the business to date to $61.6m since foundation in Switzerland in 2011.
Around 350 hospitals internationally are already using the AI company’s DDM analytics platform.
The technology is helping clinicians better diagnose thousands of patients suffering from congenital disorders and cancer every week.
Employing around 150 people, SOPHiA was shortlisted in the most recent Business Weekly Awards and narrowly missed out on honours at the presentation dinner in March. It is based locally on St John’s Innovation Park.
The new cash will help the business further refine its technology offering as well as drawing more top talent into its team. SOPHiA has tailored its platform to enable its use in a broad range of settings, from fairly basic to sophisticated.
This versatility means genomics clinicians conducting testing don’t necessarily need state-of-the-art DNA sequencing labs.
CEO and co-founder, Dr Jurgi Camblong recently told Front Line Genomics: “Our AI technology is today being deployed in 350 hospitals that are all connected to each other by a software service programme, to diagnose about 8,000 patients per month and have analysed over 125,000 patients in 53 countries to date.”
SOPHiA is looking to scale substantially into new territories, especially in The Americas and Asia Pacific.
• PHOTOGRAPH SHOWS: Mike Lynch